The Mystery of the Missing Estrogen Patches: FDA Label Changes, Demand, and HRT Alternatives

The Mystery of the Missing Estrogen Patches: FDA Label Changes, Demand, and HRT Alternatives

Duncan Turner, MD and Karen Spaulding discuss the recent shortage of estrogen patches, explaining that it stems from an FDA change in the wording of warnings on prescription estrogen products, which corrected messaging influenced by misinterpretations of the 2002 Women’s Health Initiative study. Although the safety of estrogen hasn’t changed, updated FDA verbiage prompted renewed demand that manufacturers cannot meet. They note many new inquiries are from women in their 70s who were previously told to stop HRT, and they emphasize older patients may need more complete cardiovascular evaluation before restarting. They review potential benefits of HRT for cardiovascular disease, osteoporosis, and possibly dementia, and suggest compounded transdermal estrogen creams as an effective, adjustable alternative when patches are unavailable, though often not covered by insurance.

00:00 Welcome and Setup

00:08 Why Patches Disappeared

00:22 FDA Label Change Fallout

01:33 Older Patients Returning

01:54 Who Should Restart HRT

03:02 Supply Outlook and Options

03:24 Compounded Cream Benefits

04:06 Dosing Flexibility vs Patches

04:37 Wrap Up and Next Steps